Salmeterol/fluticasone dry powder inhaler approved for asthma

AirFluSal Forspiro (salmeterol/fluticasone) is now licensed for the treatment of severe asthma, in addition to COPD.

AirFluSal Forspiro is indicated in the regular treatment of adults aged 18 years and older with severe asthma in whom use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is appropriate.

The dry powder inhaler can be prescribed for patients not adequately controlled on a lower strength corticosteroid combination product or patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.

AirFluSal Forspiro contains 50 microgram salmeterol and 500 microgram fluticasone propionate per metered dose, the same as Seretide 500 Accuhaler. One inhalation is taken twice daily.

AirFluSal Forspiro is not intended to be used for the treatment of asthma when a fixed-dose combination of salmeterol and fluticasone is required for the first time. Patients should commence treatment with a fixed-dose combination containing a lower dose of the corticosteroid component and then be titrated up until control of asthma is achieved.

Once control is achieved and it is appropriate to titrate down to a lower strength of salmeterol/fluticasone not available for AirFluSal Forspiro, a change to an alternative fixed dose combination is required.

In COPD, AirFluSal Forspiro is indicated for use in adults with a history of repeated exacerbations and significant symptoms despite regular bronchodilator therapy who have a pre-bronchodilator FEV1 that is less than 60% of the predicted normal.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases